- Sputnik International
Russia
The latest news and stories from Russia. Stay tuned for updates and breaking news on defense, politics, economy and more.

Mass Vaccination Can Start Soon as Sputnik V Production is Growing to 2Mln Doses

© Sputnik / AFK Sistema press service / Go to the mediabankProduction of anti-coronavirus vaccine Sputnik V
Production of anti-coronavirus vaccine Sputnik V - Sputnik International
Subscribe
MOSCOW (Sputnik) - The total number of produced doses of Russia's coronavirus vaccine, Sputnik V, will reach 2 million soon, making the mass immunisation of Russian citizens possible, the Ministry of Industry and Trade said on Friday.

Russian authorities have announced that the production of Sputnik V is growing ahead of the launch of a vaccination campaign.

"In the near future, the total volume of produced doses of the Sputnik V vaccine will reach 2 million, which will allow us to start the vaccination of our country's population. The production volume and the number of doses introduced into civil circulation are constantly growing", the Russian Ministry of Industry and Trade said in a press release.
© REUTERS / Matyas BorsosA laboratory assistant holds a tube with Russia's "Sputnik-V" vaccine against the coronavirus disease (COVID-19) at the National Institute of Pharmacy and Nutrition in Budapest, Hungary, November 19, 2020.
Mass Vaccination Can Start Soon as Sputnik V Production is Growing to 2Mln Doses - Sputnik International
A laboratory assistant holds a tube with Russia's "Sputnik-V" vaccine against the coronavirus disease (COVID-19) at the National Institute of Pharmacy and Nutrition in Budapest, Hungary, November 19, 2020.

Russian President Vladimir Putin has asked the government to launch mass vaccination against the coronavirus next week. Moscow Mayor Sergei Sobyanin has announced that vaccination stations will open in Moscow on Saturday. Medical personnel, social service workers, and teachers will be the first to have access to the vaccine.

Sputnik V was the first COVID-19 vaccine in the world, officially registered in Russia on 11 August. The vaccine was developed by the Gamaleya Research Institute of Epidemiology and Microbiology and is currently completing phase 3 clinical trials. Preliminary results of the drug have shown over 95 percent efficacy.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала